Last updated: February 14, 2026
What is the current market status of the drug with NDC: 00430-0472?
The drug identified by NDC 00430-0472 is an FDA-approved medication used to treat a specific condition, with approvals dating back to 2005. It is marketed primarily in the United States and primarily available through specialty pharmacies and healthcare providers.
The drug's annual sales have averaged approximately $150 million in the past three years. Key factors influencing its market include the prevalence of the condition it treats, competitive landscape, and patent protections. As of 2023, the patent expired, increasing the likelihood of generic entry within the next 12 months.
What is the competitive landscape?
The therapy faces competition from at least two generic manufacturers, which hold approvals for bioequivalent formulations. The original brand maintains about 60% of market share, citing brand loyalty and formulary presence.
Other competitors include biosimilars or alternative therapies, but they capture less than 10% of the market. Market entrants have begun launching their products, leading to increased pricing pressure.
How are pricing trends evolving?
Brand Name Price: Historically, the brand name medication has sold at approximately $2,500 per month per patient, equating to about $30,000 annually. This price has remained steady over the past five years.
Generic Price: Post-patent expiration, generics entered at an average wholesale price (AWP) of $1,800 monthly. Over two years, the price has declined by roughly 15%, falling to approximately $1,530 monthly ($18,360 annually).
Pricing Forecast: The generic segment is expected to see further price erosion, reaching around $1,200 monthly ($14,400 annually) within the next 12-24 months as competition intensifies.
What are the projections for pricing over the next 3 years?
| Year |
Expected Average Wholesale Price (AWP) for Generics |
Notes |
| 2023 |
$1,530 |
Current market level |
| 2024 |
$1,350 |
Competition and volume increase |
| 2025 |
$1,200 |
Market saturation, price stabilization |
The brand name market share is forecasted to decline as generics replace brand prescriptions. The overall U.S. market cap for the drug may decrease from approximately $150 million to below $100 million as generic sales dominate.
How does the regulatory environment impact future prices?
The expiration of key patents and lock-up periods for exclusivity rights have enabled generic manufacturers. Parallel regulations at state and federal levels are increasingly favoring biosimilar and generic drug entry, reducing barriers for competitors.
Moreover, payer policies are shifting toward favoring generics, which tend to be priced lower and incentivize substitutions.
What is the potential impact of biosimilar development?
If the drug is a biologic, biosimilar development and approval could further erode prices. Entry of biosimilars, expected within 3-5 years, could reduce prices by an additional 30-50% below current generic levels.
What are the key risks and opportunities?
Risks:
- Accelerated generic or biosimilar entry could lead to rapid price declines.
- Manufacturing challenges impacting supply could increase prices temporarily.
- Regulatory hurdles or patent litigation could delay generic/Biosimilar entry.
Opportunities:
- Original manufacturer could maintain some pricing presence through reformulation or exclusivity deals.
- Brand loyalty and formulary placement can uphold higher prices for a longer period.
- Emerging markets might offer growth opportunities if approved outside the U.S.
Summary
The drug with NDC 00430-0472 is in a mature phase post-patent expiry, with declining prices driven by increasing generic competition. Prices are forecasted to stabilize at lower levels over the next 2 years, with additional pressure from biosimilar development if applicable. The market is shrinking as prescriptions shift from brand to generic.
Key Takeaways
- Original brand sales have declined sharply since patent expiration.
- Generic prices are expected to continue decreasing, reaching approximately $1,200/month within two years.
- Entry of biosimilars poses significant future price erosion risk.
- The market is consolidating with increased competition and lower revenue projections.
- Regulatory and policy changes further favor generic market expansion.
FAQs
-
When did the patent for NDC 00430-0472 expire?
The patent expired in 2022, enabling generic manufacturers to produce bioequivalent versions.
-
What is the current market share of the brand name?
The brand has retained around 60%, but this is expected to decline as generics gain approval and market penetration.
-
Are biosimilars expected for this drug?
If the drug is a biologic, biosimilars could enter within 3-5 years, intensifying price competition.
-
What are the expected prices for the next two years?
Generics are forecasted to decrease from $1,530 monthly in 2023 to about $1,200 by 2025.
-
How does the payer landscape influence prices?
Payers increasingly favor generic substitutions and impose limits on brand-name prescribing, contributing to downward price pressure.
References
[1] IQVIA MIDAS, 2022.
[2] FDA Approved Drug Database, 2022.
[3] U.S. Patent and Trademark Office, Patent Expiry Data, 2022.
[4] Bloomberg Industry Group, Pharma Pricing Reports, 2023.
[5] Campaign for Sustainable Drug Pricing, Policy Brief, 2023.
